Goldman Sachs Future Health Care Eq ETF (GDOC)
28.59
-0.27 (-0.95%)
USD |
NYSEARCA |
May 24, 16:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.75% | -0.01% | 100.05M | 1878.23 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.00% | 9.00% | -- | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non‑U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Goldman Sachs |
| Prospectus Benchmark Index | |
| MSCI ACWI/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Anant Padmanabhan | 0.47 yrs |
| Jenny Chang | 0.47 yrs |
| Raj Garigipati | 0.47 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-3.360B
Category Low
9.492B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 24, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 24, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly and Co | 6.59% | 306.13 | 0.06% |
|
AstraZeneca PLC
|
5.18% | -- | -- |
| Boston Scientific Corp | 4.20% | 39.86 | -0.73% |
| Edwards Lifesciences Corp | 3.90% | 95.59 | 1.11% |
| Neurocrine Biosciences Inc | 3.64% | 87.13 | 2.99% |
| Seagen Inc Ordinary Shares | 3.58% | 134.44 | 0.73% |
| Intuitive Surgical Inc | 3.44% | 220.20 | 0.83% |
| West Pharmaceutical Services Inc | 3.43% | 298.47 | -0.75% |
| Halozyme Therapeutics Inc | 3.26% | 45.25 | 0.96% |
|
CSL Ltd
|
3.13% | -- | -- |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non‑U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Goldman Sachs |
| Prospectus Benchmark Index | |
| MSCI ACWI/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Anant Padmanabhan | 0.47 yrs |
| Jenny Chang | 0.47 yrs |
| Raj Garigipati | 0.47 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-24-22) | 0.00% |
| 30-Day SEC Yield (4-30-22) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 35.93 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of May 24, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 11/9/2021 |
| Last Annual Report Date | 2/28/2022 |
| Last Prospectus Date | 12/29/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)